Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 21.53 +0.06 (+0.28%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Veracyte Inc < Previous 1 2 3 4 5 6 Next > Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors June 03, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer May 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in Upcoming Investor Conferences May 15, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces First Quarter 2024 Financial Results May 07, 2024 From Veracyte, Inc. Via Business Wire 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding May 06, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 April 22, 2024 From Veracyte, Inc. Via Business Wire New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance April 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 April 16, 2024 From Veracyte, Inc. Via Business Wire Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines February 27, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results February 22, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference February 21, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 February 08, 2024 From Veracyte, Inc. Via Business Wire Veracyte Completes Acquisition of C2i Genomics February 06, 2024 From Veracyte, Inc. Via Business Wire Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform January 08, 2024 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference December 12, 2023 From Veracyte, Inc. Via Business Wire Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress December 01, 2023 From Veracyte, Inc. Via Business Wire Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules November 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 November 22, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Third Quarter 2023 Financial Results November 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally November 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Stephens Annual Investment Conference November 02, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development October 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 October 17, 2023 From Veracyte, Inc. Via Business Wire New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease October 12, 2023 From Veracyte, Inc. Via Business Wire New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier October 04, 2023 From Veracyte, Inc. Via Business Wire New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer September 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting September 21, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests September 07, 2023 From Veracyte, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.